OA07_JSW_Completers_PressRelease
Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis
November 13, 2023 06:00 ET | Biosplice Therapeutics, Inc.
Biosplice Therapeutics Inc. presents results of OA-07 Long-Term Extension Trial for its knee OA drug candidate, lorecivivint.
Biosplice logo_final RGB 300 dpi_white background.png
Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China
September 15, 2021 09:00 ET | Biosplice Therapeutics, Inc.
SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase...
Biosplice logo_final RGB 300 dpi_white background.png
Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients
July 22, 2021 10:10 ET | Biosplice Therapeutics, Inc.
Lorecivivint post-hoc analysis reveals significantly increased likelihood of symptom improvements for knee osteoarthritis compared to placebo SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Biosplice...
Biosplice logo_final 500 width_RGB_white background.png
Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform
April 15, 2021 10:55 ET | Biosplice Therapeutics, Inc.
New investors include Eventide, aMoon, SymBiosis II, Sands Capital and VeritionProceeds to support Biosplice’s clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its...